spesolimab   Click here for help

GtoPdb Ligand ID: 12169

Synonyms: BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
Approved drug Immunopharmacology Ligand
spesolimab is an approved drug (FDA and EMA (2022))
Compound class: Antibody
Comment: Spesolimab (BI-655130) is a monoclonal antibody that disrupts interleukin-36 (IL-36)/IL-36 receptor signalling. Blocking this pathway is a molecular mechanism with potential to treat inflammatory diseases in skin and other epithelial tissues [2-3,5,7], since IL-36R expression is restricted to epithelial cells that are in direct contact with the environment, including those in the skin. Spesolimab (BI-655130) appears to be related to MAB92 which was reported by Boehringer Ingelheim in 2017 [6], but we have been unable to perform direct sequence matches. The heavy and light chain sequences for spesolimab (from its INN record) are claimed in Boehringer Ingelheim's patent US9023995B2 [4].
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA and EMA (2022))
International Nonproprietary Names Click here for help
INN number INN
10845 spesolimab
Synonyms Click here for help
BI-655130 | BI655130 | spesolimab-sbzo | Spevigo®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 860
Other databases
GtoPdb PubChem SID 472319291
Search PubMed clinical trials spesolimab
Search PubMed titles spesolimab
Search PubMed titles/abstracts spesolimab